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Systemic absorption and metabolism of drugs in the small intestine, metabolism by the liver as well as
excretion by the kidney are key determinants of efficacy and safety for therapeutic candidates. However,
these systemic responses of applied substances lack in most in vitro assays. In this study, a
microphysiological system maintaining the functionality of four organs over 28 days in co-culture has been
established at a minute but standardized microsystem scale. Preformed human intestine and skin models
have been integrated into the four-organ-chip on standard cell culture inserts at a size 100000-fold
smaller than their human counterpart organs. A 3D-based spheroid, equivalent to ten liver lobules, mimics
liver function. Finally, a barrier segregating the media flow through the organs from fluids excreted by the
kidney has been generated by a polymeric membrane covered by a monolayer of human proximal tubule
epithelial cells. A peristaltic on-chip micropump ensures pulsatile media flow interconnecting the four tis-
sue culture compartments through microfluidic channels. A second microfluidic circuit ensures drainage of
the fluid excreted through the kidney epithelial cell layer. This four-organ-chip system assures near to
physiological fluid-to-tissue ratios. In-depth metabolic and gene analysis revealed the establishment of
reproducible homeostasis among the co-cultures within two to four days, sustainable over at least 28 days
independent of the individual human cell line or tissue donor background used for each organ equivalent.
Lastly, 3D imaging two-photon microscopy visualised details of spatiotemporal segregation of the two
microfluidic flows by proximal tubule epithelia. To our knowledge, this study is the first approach to estab-
lish a system for in vitro microfluidic ADME profiling and repeated dose systemic toxicity testing of drug
candidates over 28 days.Introduction
The success of organ-on-a-chip microphysiological tissue cul-
ture systems has stimulated researchers to challenge a more
systemic level of human biology in vitro through so-called
“body-on-a-chip” or “human-on-a-chip” systems.1–4 Such sys-
tems aim to combine several organ equivalents within a
human-like metabolizing environment or aim at in vivo-like
pharmacokinetics and pharmacodynamics. The first of these
microsystems – the micro cell culture analogue (μCCA) of
Shuler and colleagues5 – supports the molecular interplaybetween individual liver, bone-marrow and tumour cell line
culture compartments through a media re-circulation using
an external pump and an external common reservoir. Physio-
logical flow velocity and substance residence times can be
maintained in the system at an artificially high fluid-to-tissue
ratio. The same solution for media re-circulation has been
used in the multi-channel 3D microfluidic cell culture system
(μFCCS) of Zhang and colleagues6 to combine individual
human liver, lung, kidney, and adipose cell culture compart-
ments. By contrast, the total micro bioassay system of Imura
and colleagues,7 in its most advanced version, constitutively
combines human intestine, liver and breast cancer cell line
cultures in a single linear channel applying unidirectional
flow without media re-circulation. The advantage of these
multi-organ systems is an explicit adjustable fluid flow and a
controllable local tissue-to-fluid ratio in the channels. How-
ever, these systems suffer from reduced cross-conditioning
and reduced molecular crosstalk among tissues, due to aoyal Society of Chemistry 2015
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View Article Onlinesmall cell count (mostly below ten thousand per culture com-
partment) and a significant substance dilution. The effective
substance exposure time in most existing microsystems usu-
ally ranges from 24 to 72 hours and rarely exceeds seven
days.4 We have recently introduced a multi-organ-chip (MOC)
platform, enabling the co-culture of two different human 3D
organ equivalents, e.g. liver spheroids with skin punch bio-
psies, neuronal spheroids or intestinal tissues, at homeostasis
over weeks for repeated dose substance testing.8–10 An inte-
grated on-chip micropump and interconnecting micro-
channels support pulsatile medium perfusion at relevant
tissue-to-liquid ratios within a surrogate blood circuit of such
two-organ-chips. The combination of a human barrier organ
equivalent, such as skin, intestine or lung, with a liver model
allows the generation of data on substance absorption and
distribution between the two organs and its metabolism in
human liver tissue.
Here we aimed to extend the capability of our MOC plat-
form toward the generation of absorption, distribution,
metabolism and excretion (ADME) profiles along the timeline
of a repeated dose substance test. Therefore, we manu-
factured a MOC format able to host four human organ equiv-
alents: i) a reconstructed human 3D small intestine and ii) a
skin biopsy opting for oral and dermal substance absorption,
iii) a 3D liver equivalent enabling primary substance meta-
bolism and iv) a kidney proximal tubule compartment
supporting metabolite excretion. A robust protocol has been
established for the co-culture of these four human tissues
over at least 28 days. Here we demonstrated remarkablyThis journal is © The Royal Society of Chemistry 2015
Fig. 1 The microfluidic four-organ-chip device at a glance. a) 3D view of t
chip (footprint: 76 mm × 25 mm; height: 3 mm) accommodating a surrogat
bers represent the four tissue culture compartments for intestine (1), liver (
culture compartment aligned along the interconnecting microchannel is de
of the four-organ-chip layout illustrating the positions of three measuring
the excretory circuit. c) Average volumetric flow rate plotted against pump
cuit. Co-culture experiments were performed at 0.8 Hz and 0.3 Hz, respect
mean.robust homeostasis and functionality of the four organ equiv-
alents over the experimental period of 28 days. Barrier inte-
grity, continuous molecular transport against gradients and
metabolic activity could be demonstrated for the four-organ-
chip (4OC) co-cultures, thus making it a perfect platform for
further in vitro ADME and repeated dose toxicity testing.Materials and methods
Device design and fabrication
We designed and fabricated a microfluidic MOC device
accommodating two microphysiological fluid flow circuits,
each operated by a separate peristaltic on-chip micropump
and both overlapping in the kidney proximal tubule culture
compartment. Fig. 1a illustrates the system at a glance.
Micropump software control facilitates both clockwise and
anti-clockwise fluid flow. The peristaltic on-chip micropumps
on both circuits were modified after Wu and colleagues,11
and each represents three 500 μm-thick polydimethylsiloxane
(PDMS) membrane valves in a row. They are consecutively
actuated by applying pressure and vacuum. The cover-plates
of this 4OC accommodates six air pressure fittings, four
inserts forming culture compartments for the four different
tissue types and two additional reservoirs for fluids from the
excretory organ. The surrogate blood flow circuit comprises a
total volume of 830 μl medium, whilst the segregated
medium pool of the intestinal lumen has a volumetric capac-
ity of 250 μl and the excretory circuit holds 600 μl medium.Lab Chip, 2015, 15, 2688–2699 | 2689
he device comprising two polycarbonate cover-plates, the PDMS-glass
e blood flow circuit (pink) and an excretory flow circuit (yellow). Num-
2), skin (3), and kidney (4) tissue. A central cross-section of each tissue
picted. b) Evaluation of fluid dynamics in the 4OC using μPIV. Top view
spots (A, B and C) in the surrogate blood circuit and two spots (D, E) in
ing frequency of the surrogate blood flow circuit and the excretory cir-
ively, indicated by the vertical lines. Error bars are standard error of the
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View Article OnlineThe 4OCs were fabricated by slight modification of a
method described previously.8 In brief, two PDMS layers, the
upper small and lower large, each 2 mm thick, contain the
respective arrangement of channels, micropumps, mem-
branes and openings for culture compartments. The larger
layer was permanently bonded to a glass microscope slide
with a footprint of 75 × 25 mm (Menzel, Braunschweig, Ger-
many) by low pressure plasma oxidation (Femto; Diener,
Ebhausen, Germany), thus forming the respective fluid-tight
microfluidics with standard channel heights of 100 μm. After-
wards, a PET membrane (1 μm pores; Polyester Track Etched
(PETE) Membrane, GVS, Zola Predosa, Italy) with a diameter
of 4 mm was glued to the PDMS layer. Consecutively, the sec-
ond, smaller PDMS (21.6 × 33.6 mm) layer was permanently
bonded to the first layer by low pressure plasma oxidation,
forming the connection to the second circuit, separated from
the first and lower circuit by the PET membrane. The surro-
gate blood circuit comprises three culture compartments: i)
the intestinal culture compartment is able to hold a cell cul-
ture insert with a membrane diameter of 9 mm for the intes-
tinal tissue; ii) the liver spheroid culture compartment, which
is directly exposed to the fluid flow; and iii) the skin biopsy
culture compartment, where the biopsy tissue is shielded
from fluid flow by a standard Transwell® insert (thickness 10
μm, pore size 0.4 μm).Characterization of fluid dynamics
The microfluidic flow driven by the on-chip micropump was
regulated by an external control unit. Among others, the fre-
quency of the actuation, pressure and vacuum above the
membrane could be adjusted. Thus, the mechanical forces
conveyed by the circulating medium could be adapted to the
physiological needs of the respective organ equivalents. We
applied micro particle image velocimetry (μPIV) to determine
and adjust the flow, described in detail before.12,13 For the
flow analysis, a single chip was taken from a large batch of
freshly manufactured 4OCs. The fluid flow of the two micro-
fluidic circuits was analysed in selective spots (Fig. 1b). The
average flow rate in spots A, B and C was calculated for the
surrogate blood circuit and in D and E for the excretory cir-
cuit. We used human red blood cells (RBCs) instead of poly-
meric micro particles. Blood was obtained from donors by
venepuncture. After centrifugation at 300g for 5 min, the
plasma was discarded and the RBCs were re-suspended in
phosphate-buffered saline (PBS). A dilution of 5 × 108 cells
per ml was prepared resembling a haematocrit of about 5%.
A volume of 600 μl RBC solution was filled into the liver com-
partment and 300 μl was filled into a reservoir of the excre-
tory circuit. The residual volume of the chip was filled with
PBS. A high-speed CMOS-camera (Baumer Optronic HXC40,
Radeberg, Germany) coupled to an inverted microscope
(Zeiss Axiovert, Jena, Germany) was used to track the move-
ment of the RBCs. The exposure time was set to 4 μs per sin-
gle image; the frame rate varied, depending on the size of the
region of interest (up to 2732 fps). The size of the cells2690 | Lab Chip, 2015, 15, 2688–2699mapped was optimal at a low magnification (2.5×), which
resulted in a resolution of 0.23 px μm−1. The displacement of
the RBCs in takes of up to 16 s was calculated by the open
source MATLAB toolbox PIVlab.14,15 Further calculations were
based on the maximum velocity of the laminar plug flow in
the channels. Thus, the velocity vectors close to either side of
the channel walls were omitted. Specifically, one quarter of
the average width was neglected above and below the central
velocity field.
The spatial and temporal average velocity of the central
velocity field (vmax) was determined to calculate the flow rate
Q in each spot:
Q w h v w h k v       max (1)
where w is the average width of the respective region of inter-
est and h is the height at the same point. The coefficient k of
2/3 was determined earlier.13 It describes the relationship of
the velocity maximum (vmax) and the mean velocity v¯.
The following pump configuration was used in all experi-
ments: pressure 500 mbar, vacuum −500 mbar, and air flow
0.6 l min−1 at 350 mbar. The frequency was varied from 0.2
to 1 complete pumping cycles per s (Hz).
Human cell and tissue sources
Reconstructed human small intestinal barrier models in cell
culture inserts (EpiIntestinal™) of 9 mm size were provided
by MatTek Corporation (Ashland, MA, USA). The human
HepaRG cell line was obtained from Biopredic International
(Rennes, France). Human primary hepatic stellate cells
(HHSteC) were purchased from ScienCell Research Laborato-
ries (ScienCell, Carlsbad, CA, USA). Human juvenile prepuce
was obtained, with informed consent and ethics approval
(Ethic Committee Charité University Medicine, Berlin, Ger-
many), from a paediatric surgery after routine circumcisions,
in compliance with the relevant laws. The human proximal
tubule cell line RPTEC/TERT-1 was obtained from Evercyte
GmbH (Vienna, Austria).
Reconstruction of the intestinal barrier model
EpiIntestinal™ models are reconstructions of human
organotypic small intestine tissue models, generated from
primary human small intestinal epithelial cells that grow in
tissue culture inserts. The EpiIntestinal™ models were pro-
duced at MatTek Corporation (Ashland, USA) and were
released for a two-day overseas shipment at 4 °C after trans-
epithelial electrical resistance (TEER) levels reached a stable
range of 50–180 Ω cm2, mimicking the physiologic human
small intestine microenvironment.16–18 Upon reception, 350
μl of a specially formulated culture medium was added on
the apical side of the EpiIntestinal™ tissue. Then, the cell
culture inserts were transferred into the respective compart-
ment of the 4OC systems. Barrier models were positioned
about 100 μm above the bottom glass slide of each 4OCThis journal is © The Royal Society of Chemistry 2015
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View Article Onlinecircuit to ensure free media passage below the intestinal bar-
rier models.De novo formation of liver equivalents
Cell culture components were purchased from PAN Biotech
(Aidenbach, Germany) and cultures were incubated at 37 °C
and 5% CO2, unless otherwise stated.
The HepaRG cells were maintained, as described by
Gripon and colleagues.19 Briefly, cells were cultured in
HepaRG medium, consisting of William's Medium E
supplemented with 10% human serum, 5 μg ml−1
gentamycin, 5 μg ml−1 human insulin, 2 mM L-glutamine,
and 5 × 10−5 M hydrocortisone hemisuccinate (Sigma-Aldrich,
St. Louis, USA). Medium was renewed every two or three days.
Differentiation was initiated by maintaining the cells in
growth medium for two weeks with a regular medium
exchange every two or three days in order to reach cellular
confluence, according to the manufacturer's instructions. Dif-
ferentiation medium containing 2% dimethyl sulfoxide
(DMSO; Carl Roth GmbH, Karlsruhe, Germany) was then
added for a cultivation period of two weeks. When differenti-
ation was completed, the cells were used for further experi-
ments. Human stellate cells were expanded in Stellate Cell
Media, provided by ScienCell Research Laboratories (Carls-
bad, USA), on poly-L-lysine-coated T75 tissue culture flasks
(ScienCell, Carlsbad, USA). Cells were harvested for further
use at 80% confluence.
Human liver spheroids were formed combining HepaRG
cells and human stellate cells, as described previously,8 using
Perfecta3D® 384-Well Hanging Drop Plates (3D Biomatrix,
Ann Arbor, USA). Briefly, 20 μl cell suspension containing 4.8
× 104 hepatocytes and 0.2 × 104 HHSteC was pipetted to each
access hole. After two days of hanging drop culture, the
spheroids were transferred with wide-bore tips to ultra-low
attachment 24-well plates (Corning, Amsterdam, The Nether-
lands). Twenty spheroids were collected together to form a
single liver equivalent in the respective culture compartment
of the 4OC.Reconstruction of proximal tubule barrier model
Human proximal tubule cell line RPTEC/TERT-1 20 was used
to reconstruct the proximal tubule barrier and was cultured
in a proximal tubule cell medium, which is comprised of a 1
to 1 mixture of DMEM and Ham's F-12 nutrient mix
supplemented with 2 mM Glutamin from PAN Biotech
(Aidenbach, Germany), 5 μg ml−1 insulin, 5 μg ml−1 transfer-
rin and 5 ng ml−1 sodium selenite (ITS 1×), 100 U ml−1 peni-
cillin and 100 μg ml−1 streptomycin, 10 ng ml−1 epithelial
growth factor and 36 ng ml−1 hydrocortisone. Seven days
prior to the start of the four-organ culture, 100 000 cells were
seeded on the PET Membrane separating the two culture cir-
cuits in the 4OC. Cells were allowed to adhere to the mem-
brane overnight at static conditions. Subsequently, non-
adherent cells were removed and the flow was initiated. TheThis journal is © The Royal Society of Chemistry 2015six-day pre-culture allowed the RPTEC/TERT-1 to adjust to
the flow and to polarise.
Preparation of the skin biopsy barrier
Prepuce samples with an average size of 2.5 cm2 were stored
and transported in 10 ml PBS at 4 °C and prepared for fur-
ther culture within 4 h following surgery. They were subse-
quently incubated in 80% ethanol for 30 s. Samples with an
average thickness of 2 mm were punched to provide biopsies
of 4.5 mm diameter. Samples were loaded with the
epidermal-side up into 96-well Transwell® (Corning, Lowell,
USA) inserts and were then integrated into the respective
4OC culture compartment.
Chip-based co-cultures
The 4OC circuits were loaded with the RPTEC/TERT-1 cells
seven days prior to the start of the co-culture experiment, as
described above. In order to start the co-culture experiment,
all preloaded 4OCs were incorporated with the small intes-
tine barrier inserts, the liver equivalents and the skin biopsy
inserts. A frequency of 0.8 Hz in the surrogate blood circuit
and 0.3 Hz in the excretory circuit were chosen to ensure pul-
satile fluid flow. The height of the tissue and the amount of
medium added to the cell culture inserts enabled the tissues
to be at the air–liquid interface (skin) or submerged in media
(intestine). Three different culture media were used: i) the
small intestine culture medium containing 2.5 g l−1 glucose
and 10% human serum in the 250 μl lumen on top of the
small intestine insert; ii) the liver tissue medium containing
2.0 g l−1 glucose and 10% human serum in the 830 μl volume
of the surrogate blood circuit; and iii) the proximal tubule
cell medium containing 1.0 g l−1 glucose and no serum in the
600 μl volume of the excretory circuit. Supernatants were col-
lected twice each day from all three media pools separately:
250 μl (100%) from the intestinal lumen, 500 μl (60%) from
the surrogate blood circuit and 300 μl (50%) from the excre-
tory circuit for determination of glucose and lactate metabo-
lism. Harvested media volumes were replaced by the respec-
tive fresh medium of each medium pool. After 7, 14, 21, and
28 days of culture, tissues were removed from the 4OC and
cell behaviour, tissue architecture and transcriptional levels
of protein expression were analysed by immunohisto-
chemistry and qRT-PCR techniques. Each experimental set-
up was conducted with five replicates.
Co-culture analyses
Tissue viability was monitored daily by the measurement of
lactate dehydrogenase (LDH) released in the supernatants of
the three media pools – intestinal lumen pool (Fig. 1a,
brown), surrogate blood circuit pool (Fig. 1a, red) and excre-
tory circuit pool (Fig. 1a, yellow) – segregated from each other
by the small intestine and proximal tubule cell barriers. In
brief, samples were immediately measured for LDH activity.
All absorbance-related measurements were performed in 96-
well or 384-well microtitre plates (Corning, Amsterdam, TheLab Chip, 2015, 15, 2688–2699 | 2691
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View Article OnlineNetherlands) in a microplate reader (FLUOstar Omega, BMG
Labtech, Ortenberg, Germany), if not stated otherwise. The
LDH activity of the medium was measured using the Pierce™
LDH Cytotoxicity Assay Kit (Thermo Fisher Scientific Inc.
Waltham, USA), according to the manufacturer's instructions,
with minor modifications based on our own standard curves
LDH Positive Control (Cayman, Ann Arbor, USA): an amount
of 12.5 μl of reagent was used and 12.5 μl of the sample was
added for each measurement.
Metabolic activity of the tissues was monitored daily by
the measurement of glucose and lactate concentration in the
media supernatants of the three pools. For this, the GLU 142
(Diaglobal, Berlin, Germany) was used with minor modifica-
tions: an amount of 99 μl of reagent was used and 1 μl of
sample was added. Lactate concentration of the medium was
measured using the LAC 142 kit (Diaglobal, Berlin, Germany),
with minor modifications based on our own standard curves:
an amount of 99 μl of the reagent was mixed with 1 μl of
sample and absorbance was measured at 520 nm, using
medium as a reference.
Immunohistochemical end-point analyses were performed
by staining the liver tissue sections for cytochrome P450 3A4
(CYP3A4, mouse anti-human, Santa Cruz Biotechnology, Hei-
delberg, Germany). Skin tissues were stained for cytokeratin
10 (Ctk 10, mouse anti-human, Merck-Millipore, Darmstadt,
Germany) and cytokeratin 15 (Ctk 15, rabbit anti-human,
Abcam, Cambridge, UK), and intestinal tissue for cytokeratin
19 (Ctk 19, rabbit anti-human, DB Biotech, Kosice, Slovakia).
Briefly, representative central cryosections of the tissues were
fixed in acetone at −20 °C for 10 min and blocked with 10%
goat serum in PBS. Tissue sections were then incubated with
the respective primary antibody for 2 h and washed with PBS.
Goat anti-rabbit IgG Alexa Fluor® 594 and goat anti-mouse
FITC antibodies (all purchased from Life Technologies,
Darmstadt, Germany) were used for visualization.
Real-time qPCR endpoint analyses were performed to eval-
uate gene transcription at mRNA level after the MOC cultures2692 | Lab Chip, 2015, 15, 2688–2699
Table 1 Real-time qPCR primers to evaluate gene transcription at mRNA leve
Gene
Primer (5′ → 3′)
Forward
Intestine:
SGLT1/SLC5A1 gAgCCCAgCAACTgTCCCA
Na-K-ATPase ACCgCCCAgAAATCCCAAA
MDR1 TggATgTTTCCggTTTggAg
Kidney:
SGLT2/SLC5A2 CAACCTCAATgCCCTgCTC
Claudin 10 gggCTgTgCTCAATgACTgg
TJP3/ZO-3 gAgAAgCCAgTTTCAAgCgC
Liver:
Albumin TgCAAggCTgATAAggAg
BSEP/ABCB11 gCAgACACTggCgTTTgTTg
GSTA2 CTgAggAACAAgATgCCAA
CPY3A4 ggAAgTggACCCAgAAACTg
UGT1A1 ATgCAAAgCgCATggAgAC
MRP2 ggggACACTgTTggCTTTgTwere stopped. Tissue equivalents were collected for RNA iso-
lation using the RNeasy Mini Kit (Qiagen, Hilden, Germany).
The cDNA was synthesized by reverse transcription of 400 ng
total RNA (TaqMan1, Roche Diagnostics, Mannheim, Germany).
Real-time qPCR experiments were conducted using the Strata-
gene system (Agilent Technologies, Böblingen, Germany) and
the SensiFast SYBR No-ROX One-Step Kit (Bioline, Luckenwalde,
Germany), according to the manufacturer's instructions. The
real-time qPCR primers are shown in Table 1.
Immunofluorescence staining of RPTEC/TERT-1 cell monolayers
After culture, the membrane with the RPTEC/TERT-1 mono-
layer was removed from compartment 4 of the 4OC (Fig. 1a),
washed with PBS and fixed with 4% PFA for 10 min in a 48-
well plate. After washing, the cells were permeabilised with
0.05% Triton X-100, washed and blocked with 10% serum for
20 min. Then, the membranes were incubated with primary
antibody rabbit anti-human NaK-ATPase (Abcam, Cambridge,
UK) and mouse anti-human Cytokeratin 8/18 (Santa Cruz Bio-
technology, Heidelberg, Germany) for 2 h. Subsequently, the
membranes were washed three times and incubated with the
secondary antibody goat anti-rabbit Alexa Fluor 594 and goat
anti-mouse FITC (both Life Technologies, Darmstadt, Ger-
many) for 45 min. After washing and mounting, 3D stack
images of the samples were acquired by two-photon micros-
copy (TriMScope II; LaVision BioTec, Bielefeld, Germany).
The 3D images were reconstructed from the image stack col-
lected, using Imaris software (Bitplane, Zurich, Switzerland).
Transepithelial electrical resistance
The barrier function of the small intestinal epithelial tissue
was monitored by TEER using the Millicell ERS-2 Volt-Ohm
Meter (Millipore Co., Bedford, USA). Millicell inserts were
removed from the MOC during measurement and TEER
analysis was performed, as described by the manufacturer.
The TEER was expressed as Ω cm2 based on the area ofThis journal is © The Royal Society of Chemistry 2015
l after the MOC cultures for intestine, kidney and liver tissue
Reverse
C CAggCTCCAACACAgACggT
AC CAgCggTCATCCCAgTCC
TgTgggCTgCTgATATTTTgg
ACTgCCCCTTCCCCTTTTC
gCCCCgTTgTATgTgTATCTgg
C gTCACATCCAggAgCgCATg
TTTAgACAgggTgTTggCTTTACAC
ATgTTTgAgCggAggAACTgg
gC AgCAgAgggAAgCTggAAATAAg
C TTACggTgCCATCCCTTgAC
ggTCCTTgTgAAggCTggAg
TC CCCAgggTgCCTCATTTTCCA
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View Article OnlineTranswell® plate inserts after subtracting the resistance of
the supporting filter from the reading and multiplying it by
the surface area.
Results and discussion
Ensuring good absorption, distribution, metabolism and
excretion (ADME) properties are crucial to analyse if a drug
reaches its intended target and has a therapeutic effect with-
out causing unacceptable toxicities. However, only few drug
companies test for ADME characteristics in the early stages
of drug discovery and development.21 Current in vitro models
are lacking a systemic approach and therefore fail to predict
the interaction of metabolites between organ cultures. To
overcome this problem, we combined four human organ
equivalents through a microfluidic flow in our 4OC. On top
of the surrogate blood flow circuit, a primary human small
intestinal model was inserted in a cell culture insert (Fig. 1a)
and provided a barrier function between the apical side of
the intestine and the surrogate blood circuit, allowing
absorption. An on-chip micropump enabled the distribution
from the basolateral side of the intestinal model to a liver
equivalent, where potential substances could be metabolised.
The microfluidic channel further passed a PET membrane,
seeded with renal proximal tubule cells. This kidney model
separated the surrogate blood circuit from the second, excre-
tory circuit. In this study, we combined this ADME approach
with a skin biopsy. The skin biopsy could be either used as
an alternative absorption route or to analyse toxicity of the
parent drug or its metabolites. However, the skin could also
be replaced by any other organ equivalent, like neuronal tis-
sue, lung tissue or others, depending on the toxicity target to
be analysed. The 4OC has been designed to circulate 30–40 μl
fluid in its channel system to match a surrogate blood vol-
ume a 100 000-fold smaller than the original volume of an
adult human.22,23 Additionally, the culture compartments
surrounding the tissues provide a medium volume of about
90–120 μl, corresponding to a 100 000-fold reduction to the
original interstitial fluid in man. Finally, the four-organ-chip
consists of an artificial media reservoir of 650–680 μl above
the liver tissue culture compartment. Such a reservoir obvi-
ously does not exist in vivo. However, in the 4OC it is neces-
sary to provide sufficient nutrients to the tissues with limited
feeding rates. This artificial reservoir is envisioned to be
eliminated from the design, as soon as vascularisation of the
tissues can be accomplished and the four-organ-chip will be
transferred to oral feeding at blood perfusion.
Evaluation of fluid dynamics
Microscopic access to each and every area of the 4OC facili-
tates in-depth fluid flow analyses at various spots on the chip
(Fig. 1b and c). Two robust peristaltic on-chip micropumps,
integrated into a surrogate blood flow circuit and an excre-
tory circuit, respectively, are capable of circulating media at
sterile conditions over weeks. The flow rate ranged from 0.51
μl min−1 (at 0.2 Hz) to 3.26 μl min−1 (at 1 Hz) in the surrogateThis journal is © The Royal Society of Chemistry 2015blood flow circuit, and from 0.58 μl min−1 to 4.24 μl min−1 in
the excretory circuit. The pulse frequency in the surrogate
blood flow circuit can be increased up to 2.4 Hz, which corre-
sponds to a high but still physiological heart activity of 144
beats per min in humans. The mean velocity increased
almost linearly with the pumping frequency. The pumping
frequency used in our experiments (0.8 Hz in the surrogate
blood circuit) corresponds to 48 “heart-beats” per min
(approximately two thirds of the physiological value of an
adult at rest) to avoid untypical high shear stress in the liver
compartment. At this frequency, the medium flow rate corre-
sponds to 2.58 μl min−1. Thus, the total volume of 830 μl of
the surrogate blood circuit needs 5.3 h for a complete turn-
over. In the excretory circuit, this takes 10.4 h. The 4OC sup-
ports rectified or reversed flow in the two chambers of the
common kidney compartment, segregated by a porous mem-
brane. Here we applied reversed flow.
We successfully established μPIV using RBCs to character-
ize fluid flow profiles at different spots on the 4OC circuits.
The use of human RBCs was advantageous to synthetic
micro-particles used in our earlier fluid dynamic study13 due
to their surface potential. It prohibited the occasional adher-
ence of particles to channel walls, cells or cell residues con-
siderably. Since we used RBCs at a density suited for μPIV
measurements, no difference was observed to runs with syn-
thetic particles of a similar size (data not shown). Moreover,
we envision RBCs as an essential prerequisite for later non-
invasive online measurement of fluid flow once synthetic
media is substituted by human blood in microphysiological
MOC systems.Systemic tissue viability and barrier organ integrity
We have successfully applied LDH measurement to evaluate
the systemic viability of co-cultures in the MOC system in the
past.8 Human lactate dehydrogenase is a 140 kD enzyme
catalysing the conversion of L-lactate and NAD to pyruvate
and NADH in the final step of anaerobic glycolysis in human
cells. Here, we evaluated the LDH activity in each of the three
media pools separately. We hypothesised that LDH is not
able to pass a functional intestine or proximal tubule cell
membrane due to its size. Consequently, as long as the bar-
riers are functional, LDH values on the apical site of the epi-
thelia – in the intestinal lumen and the excretory circuit –
should be exclusively generated by the physiological turnover
of the epithelial cells, and the LDH values in the surrogate
blood circuit should be exclusively generated by a cell turn-
over, appearing in the liver equivalent and in the dermal part
of the skin equivalent. The results are summarized in Fig. 2.
After a period of 4 days, LDH levels in the 4OC normalized
toward a constant steady state in all three media pools,
indicating a constant physiological cell turnover within the
different organ compartments. The high LDH values in the
intestinal lumen and in the surrogate blood circuit at the
beginning of the 4OC co-culture are most probably related to
increased initial cell death due to shipment conditions forLab Chip, 2015, 15, 2688–2699 | 2693
Fig. 2 Systemic tissue viability in the 4OC over 28 days of co-culture
measured by LDH activity in the intestine lumen, the surrogate blood
circuit and the excretory circuit media pools, segregated from each
other by a functional small intestine and proximal tubule barrier,
respectively.
Fig. 3 Glucose balance in the three segregated media pools of the
4OC over 28 days. Bars are plotted against the background of the
physiological glucose concentration range in human blood of healthy
people (grey area). Dotted lines indicate the respective initial glucose
level of the cell culture media fed daily into the intestine lumen
(brown), the surrogate blood circuit (red) and the excretory circuit
(yellow).
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View Article Onlinethe small intestine and the damaging biopsy procedure for
the skin tissues, respectively.
By comparison, increased LDH values are repeatedly
reported in plasma or urine of patients, where they are asso-
ciated with tumour cell death or renal epithelia cell death,
respectively.24,25 It is important to consider that LDH expres-
sion in tumour cells is significantly increased in comparison
to the respective primary cells, from which the tumour cells
originate.26 This is due to the metabolic shift toward anaero-
bic glycolysis in these immortalized cells. The human
HepaRG cell line and the RPTEC/TERT-1 cell line are immor-
talized cells and, therefore, might express higher LDH levels
than primary human hepatocytes and proximal tubule cells
at an individual cell level. This might explain the detectable
LDH levels in the surrogate blood circuit and the excretory
circuit during the entire co-culture period. The higher LDH
levels in the intestinal lumen of the 4OC are related to the
high turnover of small intestine epithelia, which is in the
range of 3–5 days.27 Finally, the differences in LDH activity of
the three media pools is a first clear indicator of the biologi-
cal integrity of the small intestine and proximal tubule cell
barriers in the 4OC. A more reliable indicator of the biologi-
cal integrity and functionality of human intestinal or proxi-
mal tubule barriers is the glucose balance generated by these
barriers in the context of different high glucose challenges
on both sides of each barrier. Glucose concentration mea-
sured in the media pools over the 28-day co-culture are sum-
marized in Fig. 3. The amount of glucose stored in the
human body is approx. 450 g and 250 g is turned over daily.
The normal Western diet provides 180 g glucose per day and
the gap between the amount in food and the amount utilised
is bridged by stored glucose and gluconeogenesis mainly in
the liver and kidneys.28 The brain alone utilises 125 g of the
daily glucose turnover. We extrapolated a daily turnover of
less than 1.2 mg glucose for the four organ equivalents co-
cultured in the 4OC, which were established at a size
100 000-fold smaller than their original counterpart organs.2694 | Lab Chip, 2015, 15, 2688–2699We supplemented glucose in excess of close to 2.2 mg every
day to the three media pools – 0.62 mg into the intestinal
lumen, 1.25 mg into the surrogate blood circuit and 0.3 mg
into the excretory circuit – to evaluate the response of the tis-
sues at non-physiologically high amounts of glucose. Homeo-
static mechanisms maintain blood glucose within narrow
limits of 0.65 g l−1 and 1.1 g l−1 to ensure that an adequate
amount of energy is provided to the organs of the body. Glu-
cose is usually absorbed completely in the small intestine.
The kidneys assist in keeping blood glucose levels normal by
reabsorbing the filtered 180 g of glucose at the glomeruli. Vir-
tually no glucose appears in the urine (<0.5 g per day)
because of the presence of glucose transporters in the proxi-
mal tubule.28 Here, we report a remarkably stable glucose
balance in the three media pools, which has been established
in the 4OC system over the entire period of the 28-day co-cul-
ture of the four tissues (Fig. 3). The glucose level in the surro-
gate blood circuit was constantly decreased to values fitting
into the narrow range of normal blood glucose. Glucose con-
centration in the intestinal lumen decreased at least four-fold
in comparison to the initial medium content of 2.5 g l−1.
Finally, the lowest level of glucose was constantly present in
the excretory circuit, although this value never dropped to
zero.
The ability of the barrier models to maintain gradients
between the three medium compartments was additionally
verified by protein concentration measurements (data not
shown).
Transepithelial electrical resistance (TEER) measurements
were performed for intestinal tissues. The TEER values stayed
constant over the culture time and ranged from 75 to 195 Ω
cm2, indicating an intact and physiological barrier, compara-
ble to the human intestine, where TEER values range from 50
to 120 Ω cm2.16,17
The distinct glucose and protein concentration gradients
between the three media pools and the consistent TEER
values verify the functional integrity of the intestinal and the
proximal tubule cell barriers throughout the entire co-culture.This journal is © The Royal Society of Chemistry 2015
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View Article OnlineFour-organ-co-culture performance
At the end of the 28 day co-culture period, we investigated
the tissue architecture of the different organ equivalents
using immunohistochemical staining. Fig. 4 illustrates the
prime findings of these analyses. The human small intestine
barrier exhibited a perfect physiological polarisation, as
shown by Ctk 19 expression along the crypt-villus axis
(Fig. 4a). In humans, Ctk 19 is present along the entire crypt-
villus axis and is mainly expressed in the apical domain of
polarised cells. Its downregulation has been shown to
decrease the number of microvilli and derange the targeting
of apically distributed proteins.29–31 Remarkably, in addition
to the microvilli expression, human small intestine epithelia
form a villi-like 3D architecture of up to 270 μm height in the
4OC co-culture. Such villi-like structures have rarely been
shown to appear to a maximum height of 130 μm in CaCo-2
cell models – the current gold standard for an intestinal bar-
rier in vitro – when shear stress is applied.32 Here, we report
such an architectural self-assembly without periodical shear
stress applied to the apical site of the intestinal model. TheThis journal is © The Royal Society of Chemistry 2015
Fig. 4 Performance of human tissues in the 4OC after 28 days of co-cult
tissue, b) CYP3A4 (green) expression in liver aggregates, c) epidermal mark
ATPase (red) and Ctk 8/18 (green) in proximal tubule epithelial monolayer. (self-assembly capacity of the primary human small intestine
epithelia within the right microenvironment might be a pos-
sible explanation for this reproducible phenomenon.
Three-dimensional spheroids of hepatocytes co-cultured
with human stellate cells, the fibroblasts of the liver, preserve
their initial well-defined 3D architecture over the entire co-
culture period. Moreover, they still express the key CYP3A4,
as exemplarily demonstrated in Fig. 4b.
Skin biopsies reveal a fully functional, proliferative and
differentiated epidermis, as staining of epidermal markers
Ctk 10 and 15 showed (Fig. 4c). The culture at a physiological
air–liquid interface facilitates the maintenance of a stratified
stratum corneum, thus providing an in vivo-like architecture
for topical substance administration. Various successful
MOC experiments with skin biopsies, reconstructed skin and
a combination of both have been performed in the past,8,33
verifying the robustness and flexibility of the platform.
Finally, polarisation of the Na-K-ATPase at the basolateral
surface of the human proximal tubule cell layer indicates dis-
tinct transport function of the sodium-potassium pump dur-
ing the 28-day co-culture in the 4OC.Lab Chip, 2015, 15, 2688–2699 | 2695
ure. Staining a) for Ctk 19 (red) expression in small intestinal epithelial
ers Ctk 10 (green) and Ctk 15 (red) in skin biopsies, d) transporter NaK-
a–d) Nuclei were stained with DAPI (blue). Bars = 100 μm.
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View Article OnlineIn order to further evaluate the functional integrity and
capabilities of the established organ equivalents to absorb,
distribute, metabolise, reabsorb and excrete molecules, we
applied gene expression analysis for selected genes associ-
ated with these processes. To investigate the cell barriers of
the small intestine (Fig. 5a) and proximal tubule (Fig. 5b) we
focused on the expression of the major active sodium-
coupled glucose transporters SLC5A1 playing a central role in
intestinal glucose absorption,28 and SLC5A2 (SGLT2 gene
family), crucial for renal proximal tubule glucose
reabsorption34 (Fig. 5a, b). Both transporters are constitu-
tively expressed in their respective tissues over the entire co-
culture period. Remarkably, glucose is present in the glomer-
ular filtrate in vivo and is, under usual circumstances,
completely reabsorbed by SGLT2 transporters of proximal
tubule cells. Recent observations have shown that diabetic
patients up-regulate the expression of SGLT2 renal glucose
transporters, presumably to compensate for and reduce gly-
cosuria.35 The higher expression of SLC5A2 in the 4OC might
be the result of a similar up-regulation due to the exposure of
the proximal tubule cells to the high glucose levels in the sur-
rogate blood circuit and the excretory circuit. However, com-
paring these expressions to conventional culture methods,
the expression was 2.5 fold lower in cells cultured under fluid
flow (data not shown).2696 | Lab Chip, 2015, 15, 2688–2699
Fig. 5 Gene expression in co-cultures of the four-organ-chip over 28 day
Na-K-ATPase and MDR1 expression. b) Reabsorption and consequently exc
the expression of SLC5A2. The expression of Claudin-10 and TJP3 underpin
tissue is verified by stable steady state expression of Albumin, BSEP and G
capability to perform phase I, phase II and phase III metabolism is exemplarThe expression of the sodium–potassium ATPase in the
small intestine is a prime prerequisite for the maintenance
of physiological ion gradients across the cell membrane and
the associated molecular transport capacity. The expression
of the sodium–potassium ATPase stayed constant over the
culture period. Finally, multidrug resistance transporters,
such as MDR1, provide a general protection against hydro-
phobic xenobiotics in intestine and all other human tis-
sues.36 Over the culture period of 28 days, the mRNA expres-
sion of MDR1 in the intestinal tissue increased slightly, but
not significantly. The stable expression of these targets dem-
onstrates the homeostasis of the tissue within the 4OC
culture.
Tight junctions are membrane proteins that close the
intercellular space in epithelial cells. They act as a para-
cellular barrier regulating the passage of ions, water and vari-
ous macromolecules. Additionally, they maintain epithelial
cell polarity and thus prevent intermixture of membrane
components of the apical with those of the lateral side.
Claudin-10 is concentrated within the tight junctions of prox-
imal tubule epithelial cells and is responsible for the forma-
tion of tight junction strands.37 Tight junction protein 3 (ZO-
3) is involved in cell proliferation and epithelial homeostasis
through complex formation with cyclin D1.38 The constitutive
expression of claudin-10 and TJP3 in the proximal tubuleThis journal is © The Royal Society of Chemistry 2015
s. a) Absorption potential of the intestine barrier is verified by SLC5A1,
retion capability of the kidney proximal tubules cell barrier is verified by
s barrier integrity and cell turnover. c) Physiological function of the liver
STA2 at their discrete levels over the entire co-culture period. d) Liver
ily shown by expression of CYP3A4, UGT1A1 and MRP2 respectively.
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View Article Onlinecells indicates physiological function of the tight junctions of
this barrier throughout the co-culture period.
Physiological function of the liver tissue in the 4OC co-
cultures is verified by the stable steady-state expression of
albumin, bile salt export pump (BSEP) and GSTA2 at their
discrete levels over the entire co-culture period of 28 days
(Fig. 5c). Albumin is constitutively expressed at high levels.
Its secretion into the medium circulation of MOCs has
been demonstrated before.8 The BSEP or sPgp (sister of
P-glycoprotein) is the product of the ABCB11 gene. The activ-
ity of this transporter in humans is the major determinant of
bile formation and bile flow. This particular protein is
responsible for the transport of taurocholate and other cho-
late conjugates from hepatocytes to the bile.39 Its consistent
expression indicates functional bile formation over the 28
days. A major remaining drawback of each and every cur-
rently existing liver-on-a-chip model is the lack of bile
removal from the liver equivalent through a channel system,
segregated from the main medium circuit, as summarized in
a respective review.40 Glutathione S-transferase (GSTA2) plays
a key role in detoxification of electrophilic compounds by
conjugation with glutathione. Therefore, it protects cells from
reactive oxygen species and products of peroxidation. Its con-
stant expression serves as a marker of the self-protective
capacity of the liver equivalent in the co-culture.
The capability of the liver model to perform phase I, II
and III metabolism is exemplarily shown by expression of
CYP3A4, UGT1A1 and MRP2, respectively (Fig. 5d). CYP3A4
is an important phase I metabolism enzyme acting by
oxidising xenobiotics. A high expression of CYP3A4 can be
seen at day 0 before culture. The expression was reduced
after 4 days of culture (data not shown) and stayed constant
over the following 25 days of culture, at a comparable expres-
sion level observed in previous cultures.8,10 The high expres-
sion of CYP3A4 at day 0 of culture is related to the pre-
culture in 2% DMSO for differentiation of HepaRG prior
to the co-culture, as DMSO considerably induces CYP3A4
activity.41 This supports the previous findings, indicating that
the system needs 3 to 4 days to adapt to the new micro-
environment in order to establish a reproducible homeosta-
sis. A potential substance application should therefore only
start after a 4 day adaption phase. Uridine 5′-diphospho-
glucuronosyltransferase (UGT1A1) transforms small lipo-
philic molecules, such as steroids, bilirubin, hormones, and
drugs, into water-soluble, excretable metabolites.42 It is a
major enzyme of the phase II metabolism in the liver. Multi-
drug resistance-associated protein 2 is expressed in the cana-
licular (apical) part of the hepatocyte and functions in biliary
transport (Phase III metabolism). The discrete expression of
the three key metabolic proteins, each acting in a different
phase of the metabolism, verifies that the liver equivalent
has a broad and stable metabolic capacity throughout the
entire co-culture period of 28 days. The addition of antibi-
otics to the culture medium during co-culture exposes a
constant stimulation of xenobiotic metabolism in the liver
equivalent of the 4OC.This journal is © The Royal Society of Chemistry 2015Conclusions
For the first time, we report a microphysiological four-organ-
chip system that enables a reproducible 28 day co-culture of
four tissues. All tissues maintained a high cell viability and
discrete physiological tissue architecture over the entire co-
culture period. The human small intestine epithelia formed
stable 3D villi-like structures of up to 270 μm height and
expressed an apical brush border. Skin biopsies developed a
stratified stratum corneum at the air–liquid interface. The
human proximal tubule epithelia maintained a functional
polarised monolayer barrier. Small intestine and kidney prox-
imal tubule cell barriers were able to keep a continuously sta-
ble glucose gradient balance between the intestinal lumen,
the surrogate blood circuit and the excretory circuit of the
system. Moreover, in-depth metabolic and gene analysis
revealed the establishment of a reproducible homeostasis
between all four tissues over at least 28 days independent of
the individual human cell line or tissue donor background
used for each organ equivalent. The four-organ-chip presented
here has been designed to support ADME profiling of sub-
stances along with repeated dose systemic toxicity testing of
drug candidates. We could demonstrate integrity and func-
tionality of the intestine and the kidney biological barriers
at a physiologically relevant organ downscale. A separate
medium reservoir at the apical surface of the intestinal bar-
rier allows for “oral” administration of a drug compound.
Following absorption, a drug will reach the surrogate blood
circulation mimicking the plasma compartment. Subse-
quently, a drug compound will be distributed to the liver
equivalent followed by the skin and the kidney equivalent.
This arrangement of our four-organ-chip enables physiologi-
cal absorption, first path metabolism in the liver tissue, sec-
ondary metabolism and finally excretion through the kidney
model. Permanent access to the different compartments and
the organ equivalents themselves enable to evaluate pharma-
cokinetic and pharmacodynamics parameters, such as effec-
tive concentration, maximum tolerable dose, time course and
intensity of therapeutic and adverse effects.
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